Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study

Contraception

Volumn 76, Issue 3, 2007, Pages 228-232

  Guo, Zhiyong ^a   Wang, Sui ^a   Wei, Danyi ^a   Zhai, Jinxia ^b  

^a NINGBO UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

High performance liquid chromatography; Internal standard; Mifepristone; Norethisterone; Pharmacokinetic; Solid phase extraction

Indexed keywords

ACETONITRILE; MIFEPRISTONE; NORETHISTERONE; WATER;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CALIBRATION; CLINICAL TRIAL; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DRUG DETERMINATION; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; SPECTRAL SENSITIVITY; STANDARD; ULTRAVIOLET RADIATION; VALIDATION STUDY;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HUMANS; MIFEPRISTONE; NORETHINDRONE;

EID: 34547841576     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.04.004     Document Type: Article

References (16)

1. Baulieu E.E. The antiprogestin steroid RU 486 and human fertility control (1985), Plenum Press, New York
2. Ulmann A., Teutsch G., and Philibert D. RU 486. Sci Am 262 (1990) 42-48
3. Mahajan D.K., and London S.N. Mifepristone (RU486): a review. Fertil Steril 68 (1997) 967-976
4. Steinauer J., Pritts E.A., Jackson R., and Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103 (2004) 1331-1336
5. DeBattista C., and Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrin Med 17 (2006) 117-121
6. Heikinheimo O., Kekkonen R., and Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 68 (2003) 421-426
7. Leminen R., Ranta S., Hertzen H., Oehler J., and Heikinheimo O. Pharmacokinetics of 10 mg of mifepristone. Contraception 68 (2003) 427-429
8. Kekkonen R., Heikinheimo O., Mandelin E., and Lähteenmäki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 54 (1996) 229-234
9. Wang J., Shi W., Zhang G., and Bai X. Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone. Contraception 49 (1994) 245-253
10. Kawai S., Nieman L.K., Brandon D.D., Udelsman R., Loriaux D.L., and Chrousos G.P. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone RU 486 in man. J Pharmacol Exp Ther 241 (1987) 401-406
11. Földesi I., Falkay G., and Kovács L. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception 54 (1996) 27-32
12. Heikinheimo O., Tevilin M., Shoupe D., Croxxato M., and Lähteenmäki P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 34 (1986) 613-624
13. He C., Shi Y., Ye Z., Zhang G., Jiang N., Van Look P.F.A., et al. Pharmacokinetic study of orally administered RU 486 in non-pregnant women. Contraception 40 (1989) 449-460
14. Stith C., and Hussian M.D. Determination of mifepristone levels in wild canid serum using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 794 (2003) 9-15
15. Guo Z., Chu C., Yin G., He M., Fu K., and Wu J. An HPLC method for the determination of ng mifepristone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 832 (2006) 181-184
16. Vial J., and Jardy A. Experimental comparison of the different approaches to estimate LOD and LOQ of an HPLC method. Anal Chem 71 (1999) 2672-2677